Breast Cancer Program
PI: Eric Winer, MD (DFCI)
- Androgens, Androgen Receptor Signaling and Breast Carcinogenesis
Co-Leaders: Myles Brown, MD (DFCI) and Rulla Tamimi, ScD (BWH)
Overcoming Resistance to HER2-directed Therapies for Breast Cancer
Co-Leaders: Thomas Roberts, PhD (DFCI) and Ian Krop, MD, PhD (DFCI)
Novel Strategies to Extend DNA Repair Therapies for Triple Negative Breast Cancer
Co-Leaders: Alan D’Andrea, MD (DFCI) and Judy Garber, MD, MPH (DFCI)
BET Bromodomain Proteins as Novel Therapeutic Targets in Triple Negative Breast Cancer
Co-Leaders: Kornelia Polyak, MD, PhD (DFCI) and Eric Winer, MD (DFCI)
Dec 12Seminars in Oncology: "Prioritizing Variants in Personal Genomes"
Dec 12Harvard Surgical Speaker Series: J. Michael McWilliams "Accountable Care Organizations: Happy Talk, Evidence, and Challenges Ahead"
Dec 13Prognosis Talk and Patient-Centered Outcomes: findings from the Palliative Care Communication Research Initiative cohort study